MPLT Company Profile and Key Details

NASDAQ : MPLT

MapLight Therapeutics

$31.96

1.31+4.27%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

MapLight Therapeutics, Inc. (MPLT) stock surged +4.27%, trading at $31.96 on NASDAQ, up from the previous close of $30.65. The stock opened at $30.88, fluctuating between $30.86 and $32.47 in the recent session.

Stock Snapshot

30.65

Prev. Close

25.23M

Market Cap

30.86

Day Low

-0.83

P/E Ratio

-38.52

EPS (TTM)

N/A

Cash Flow per Share

30.88

Open

789.34K

Number of Shares

32.47

Day High

N/A

Free Float in %

N/A

Book Value

456.56K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 25, 2026	30.88	32.47	30.86	31.96	463.26K
Jun 24, 2026	28.61	30.74	28.18	30.65	386.26K
Jun 23, 2026	28.33	30.19	28.33	28.64	360.12K
Jun 22, 2026	27.98	31.52	27.98	29.79	654.79K
Jun 18, 2026	30.01	30.41	28.66	28.82	1.47M
Jun 17, 2026	27.21	29.56	27.21	29.21	410.72K
Jun 16, 2026	27.97	28.57	26.74	27.16	203.08K
Jun 15, 2026	27.89	28.43	27.07	27.96	204.99K
Jun 12, 2026	30.85	31.28	27.44	27.75	324.4K
Jun 11, 2026	27.93	30.81	27.75	30.35	255.45K
Jun 10, 2026	29.32	30.51	27.66	27.80	184.02K
Jun 09, 2026	29.83	30.60	28.14	29.27	251.91K
Jun 08, 2026	28.40	29.58	27.61	29.46	235.09K
Jun 05, 2026	30.10	30.10	27.15	28.01	478.19K
Jun 04, 2026	28.20	30.93	27.76	30.10	397.28K
Jun 03, 2026	27.26	28.37	25.66	28.34	191.73K
Jun 01, 2026	28.99	30.03	28.40	29.76	270.55K
May 29, 2026	29.56	30.69	29.12	29.31	436.94K
May 28, 2026	29.26	30.37	28.60	29.78	485.68K
May 27, 2026	29.99	30.83	29.29	29.55	269.27K

Contact Details

Redwood City, CA 94063

United States

https://www.maplightrx.com 617 984 6300

About Company

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.

Stock Peers

ARGX

36.15+4.24%

argenx SE$888.65 REGN

-3.29-0.53%

Regeneron Pharmaceuticals, Inc.$620.14 UTHR

-6.51-1.18%

United Therapeutics Corporation$543.39 MDGL

4.03+0.79%

Madrigal Pharmaceuticals, Inc.$513.79 VRTX

4.98+1.05%

Vertex Pharmaceuticals Incorporated$480.18 KRYS

12.3+3.54%

Krystal Biotech, Inc.$359.93 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

18.92+6.12%

Praxis Precision Medicines, Inc.$327.86 LGND

11.01+3.86%

Ligand Pharmaceuticals Incorporated$295.92 ALNY

-0.89-0.30%

Alnylam Pharmaceuticals, Inc.$293.17

Company Overview

MapLight Therapeutics, Inc. (NASDAQ:MPLT) closed at $31.96 USD, gaining $1.31 (4.27%) from the previous close of $30.65. The stock is currently within 5% of its 52-week high $12.24 and $33.28. With a market capitalization of about $25.23 million, MapLight Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.34). Key stats such as the average daily volume over the past year has been around 327.37 thousand shares, in line with its 52-week average. Headquartered in Redwood City, CA, MapLight Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Christopher A. Kroeger, the company employs approximately 109 people and listed since October 24, 2025. MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -0.51%, SMA50 -3.0%, SMA200 1.57%). The stock’s 14-day RSI is 47.91 (neutral), while the ATR of 1.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.16% below its high and over 42.32% above its low. Average 10-day trading volume of 563.59 thousand shares is significantly above the 3-month average of 324.21 thousand, indicating heightened recent market interest.

Valuation Metrics

MapLight Therapeutics, Inc. trades at a P/E ratio of -6.97, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.61 trading at moderately above to book value. The P/FCF stands at -0.15, also above market averages.

Dividend & Fair Value

MapLight Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.93. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $48.00 to $28.00. The high target offers 50.19% upside. The low target suggests -12.39% downside. The mean target is $38.64. This offers 20.9% upside. MapLight Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by 39.29%. The prior quarter beat by 135.24%. Over the last six quarters, Apple has recorded several small beats. These include 2055.36% in December 04, 2025.

Shareholding & Insider Activity

MapLight Therapeutics, Inc. has 45.37 million shares outstanding. The public float is 172.42 million shares, elevated short interest at 3.07% of float. This equals 1.37 million shares. The short ratio is 6.89 days.

Financial & Profitability Overview

Over the trailing twelve months, MapLight Therapeutics has not generated any revenue.
On valuation metrics, MapLight Therapeutics trades at a P/E of -6.97, P/S of 0.00 and P/B of 3.61. The current ratio is 22.91 and quick ratio is 22.91. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -29.29.

Price Forecast & Outlook

Our AI price prediction model suggests that MapLight Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.03%, with price expected at $31.63 by July 09, 2026, within a range of $30.38 to $32.84 3-Month Outlook: Projected fall of -20.31%, reaching $25.47 by September 22, 2026, with a range of $25.13 to $25.85. 1-Year Outlook: Projected gain of 83.07%, with price at $58.51 by June 25, 2027, within a range of $57.92 to $59.07.

Key Takeaways

MapLight Therapeutics, Inc. (NASDAQ:MPLT) shares are flat -3.05% year-to-date currently trading near 52-week highs band. Valuation shows MapLight Therapeutics, Inc. trading at a premium to the broader market with a P/E of -6.97. Analyst sentiment is cautious, with the majority of ratings in Strong Buy territory and a mean price target of $38.64, suggesting 20.9% upside. Our AI forecast model points to short-term weakness (-1.03% over two weeks), a medium-term fall (-20.31% over three months), and a longer-term gain (83.07% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current MapLight Therapeutics, Inc. (MPLT) stock price?

MapLight Therapeutics, Inc. (NASDAQ: MPLT) stock price is $31.96 in the last trading session. During the trading session, MPLT stock reached the peak price of $32.47 while $30.86 was the lowest point it dropped to. The percentage change in MPLT stock occurred in the recent session was 4.27% while the dollar amount for the price change in MPLT stock was $1.31.

MPLT's industry and sector of operation?

The NASDAQ listed MPLT is part of Biotechnology industry that operates in the broader Healthcare sector. MapLight Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MPLT?

No Data

How MPLT did perform over past 52-week?

MPLT's closing price is 161.11% higher than its 52-week low of $12.24 where as its distance from 52-week high of $33.28 is -3.97%.

How many employees does MPLT have?

Number of MPLT employees currently stands at 109.

Link for MPLT official website?

Official Website of MPLT is: https://www.maplightrx.com

How do I contact MPLT?

MPLT could be contacted at phone 617 984 6300 and can also be accessed through its website. MPLT operates from 800 Chesapeake Drive, Redwood City, CA 94063, United States.

How many shares of MPLT are traded daily?

MPLT stock volume for the day was 456.56K shares. The average number of MPLT shares traded daily for last 3 months was 327.37K.

What is the market cap of MPLT currently?

The market value of MPLT currently stands at $25.23M with its latest stock price at $31.96 and 789.34K of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	109
Beta	2.34
Sales or Revenue	N/A
5Y Sales Change%	N/A
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

MPLT Company Profile and Key Details

MapLight Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Key Takeaways

Price Forecast & Outlook

Company Overview

Valuation Metrics